| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalaris Therapeutics, Inc. (KLRS) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. KLRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.22M | $10.50M | - | |
| CFO | 235.0K | $1.11M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2024 | Miller Edward82 | General Counsel | Sell | 379 | $0.72 | $272.88 | -0.2% | +10.0% | -84.9% | |
| Jul 2, 2024 | Sinha Vikas84 | See Remarks | Sell | 939 | $0.72 | $676.08 | - | +10.0% | -84.9% | |
| Jul 2, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 304 | $0.72 | $218.88 | -0.4% | +10.0% | -84.9% | |
| Jul 2, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 1,489 | $0.72 | $1,072.08 | -0.2% | +10.0% | -84.9% | |
| May 21, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 5,149 | $0.79 | $4,079.55 | -0.7% | -3.5% | -83.7% | |
| May 17, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 541 | $0.75 | $405.37 | -0.7% | -5.8% | -80.5% | |
| May 17, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 3,075 | $0.75 | $2,304.10 | -0.4% | -5.8% | -80.5% | |
| May 17, 2024 | Sinha Vikas84 | See Remarks | Sell | 3,143 | $0.75 | $2,355.05 | -0.3% | -5.8% | -80.5% | |
| May 17, 2024 | Miller Edward82 | General Counsel | Sell | 420 | $0.75 | $314.71 | -0.2% | -5.8% | -80.5% | |
| May 3, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 10,240 | $0.80 | $8,151.04 | -1.3% | +0.3% | -68.2% |